Navigation Links
New Hepatitis B Vaccine

Hepatitis B infection is the world's most common liver infection. It spreads easily and is readily transmitted to individuals than the AIDS virus.

It causes liver cirrhosis, // liver failure and liver cancer. Statistics show that about two billion people (30 %) of the world's population, has been infected with the hepatitis B virus.

Out of which 350 million individuals are chronic carriers of the virus. Normally in case of adults the immune system clears about 95% of the virus from the body.

But in case of infants who are commonly affected the body fails to clear the virus and the patient often remain chronically infected.

Researchers at the flinders Medical Centre did various experiments to find a cure for the world's most common and deadly liver infection, hepatitis B.

This resulted in the development of the new vaccine which is thought to be very effective against the virus. Professor Nikolai Petrovsky said the new formula was designed to make the medication safer and more effective than existing vaccines.

It would facilitate the immune system to attack, destroy and expel the hepatitis virus more effectively. It is a boon for those who respond poorly for the current hepatitis B vaccines, including people with immunodeficiency, diabetes, elderly people and people with kidney disease.

This has come about to prevent the death of about one million people who die from liver failure as a result of hepatitis B infection across the worldwide.

The initial trail of the vaccine is mainly aimed in testing the safety and effectiveness of the vaccine, but future trials will test whether it is capable of being a cure for chronic hepatitis B infection.

The new vaccine includes a special booster derived from a natural sugar found in dahlia flowers.


'"/>




Page: 1

Related medicine news :

1. Vitamin B for Hepatitis
2. Hepatitis G May Boost HIV Survival
3. Cure for Hepatitis B
4. Hepatitis E virus made impotent
5. Sharing injection equipment spreads Hepatitis C
6. Lymphomas Link to Hepatitis C
7. Hepatitis shots is promising
8. Need for Hepatitis Booster Questioned
9. Good News for HIV Patients Also Suffering From Hepatitis C Virus
10. The Link Between Hepatitis B Vaccine And Multiple Sclerosis Questioned
11. The Effectiveness Of Hepatitis B Vaccine Questioned
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a ... Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, which ... to individuals and corporations which donate directly to a “rural hospital” in Georgia, and ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... ... 2016 , ... Mobility Designed is redefining mobility with their patent pending ... Crutch evenly distributes body weight from the elbow to the forearm. In consumer ... than with other crutches. , Co-founders Max and Liliana Younger were inspired to design ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology: